CA2035868A1 - Molecules hybrides - Google Patents

Molecules hybrides

Info

Publication number
CA2035868A1
CA2035868A1 CA002035868A CA2035868A CA2035868A1 CA 2035868 A1 CA2035868 A1 CA 2035868A1 CA 002035868 A CA002035868 A CA 002035868A CA 2035868 A CA2035868 A CA 2035868A CA 2035868 A1 CA2035868 A1 CA 2035868A1
Authority
CA
Canada
Prior art keywords
hybrid molecule
cells
hybrid
cytokine
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002035868A
Other languages
English (en)
Inventor
Richard C. Svrluga
Cory A. Waters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2035868A1 publication Critical patent/CA2035868A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002035868A 1989-07-06 1990-07-06 Molecules hybrides Abandoned CA2035868A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US376,656 1982-05-10
US37665689A 1989-07-06 1989-07-06

Publications (1)

Publication Number Publication Date
CA2035868A1 true CA2035868A1 (fr) 1991-01-07

Family

ID=23485915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002035868A Abandoned CA2035868A1 (fr) 1989-07-06 1990-07-06 Molecules hybrides

Country Status (4)

Country Link
EP (1) EP0433442A4 (fr)
JP (1) JPH04501808A (fr)
CA (1) CA2035868A1 (fr)
WO (1) WO1991001004A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE123065T1 (de) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
ATE167896T1 (de) * 1990-08-29 1998-07-15 Genetics Inst Aus mehreren domänen bestehende hämatopoese- stimulatoren
AU8735991A (en) * 1990-09-28 1992-04-28 Ortho Pharmaceutical Corporation Hybrid growth factors
AU705327B2 (en) * 1991-03-07 1999-05-20 Seragen, Inc. Use of cell surface receptor targeted molecules for the treatment of viral diseases
WO1992015318A1 (fr) * 1991-03-07 1992-09-17 Seragen, Inc. Utilisation de molecules ciblees sur des recepteurs de surface de cellules pour le traitement des maladies virales
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
WO1992020364A1 (fr) * 1991-05-17 1992-11-26 Seragen, Inc. Molecules ciblees sur un recepteur de cytokine par le traitement de la croissance de cellules neoplasiques
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
CZ304942B6 (cs) 2000-03-31 2015-02-04 Purdue Research Foundation Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
AU2002216763B2 (en) * 2000-06-30 2007-03-01 University Of Louisville Research Foundation, Inc. Alteration of cell membrane

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158198A1 (fr) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. ADN et son utilisation

Also Published As

Publication number Publication date
WO1991001004A1 (fr) 1991-01-24
EP0433442A1 (fr) 1991-06-26
EP0433442A4 (en) 1992-08-05
JPH04501808A (ja) 1992-04-02

Similar Documents

Publication Publication Date Title
CA2035868A1 (fr) Molecules hybrides
AU2001275246B2 (en) T cell receptor fusions and conjugates and methods of use thereof
Robinson et al. A glycophospholipid anchor is required for Qa-2-mediated T cell activation
US5705156A (en) Psuedomonas exotoxins of low animal toxicity and high cytocidal activity
FI120042B (fi) Menetelmä kasvainkuoliotekijän reseptoria sisältävien fuusioproteiinien valmistamiseksi ja niitä koodaavia polynukleotideja ja vektoreita
EP0583794B1 (fr) Exotoxine récombinante de Pseudomonas: construction d'une immunotoxine active avec effets secondaires faibles
US5080898A (en) Enzymatically active toxin coupled to a cell-specific ligand
AU2001275246A1 (en) T cell receptor fusions and conjugates and methods of use thereof
AU758839B2 (en) Methods of cancer diagnosis using a chimeric toxin
EP0246307B1 (fr) Adn modifie par un codon cys
CA2169629C (fr) Fragment de recepteur d'erythropoietine chez l'homme et anticorps
Lorberboum-Galski et al. IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.
US6008319A (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2182682A1 (fr) Molecules immuno-interactives i
AU697469B2 (en) Intracellular delivery of chemical agents to a specific cell type
CA2083487A1 (fr) Toxynes chimeriques avec domaine structural a geometrie amelioree
EP0341304A1 (fr) Molecules de ricin et conjugues de toxines de ricin ameliores
MXPA97001860A (en) Intracellular supply of chemical agents, to a specific unit of cel
EP0931836B1 (fr) Peptide dérivé de l'interleukine-2 humaine pouvant accroître la perméablilté vasculaire et les immunoconjugués en dérivant
AU625534B2 (en) Interleukin-1 receptors
US20040156824A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
AU689231B2 (en) Immunointeractive molecules-I
WO1995015379A1 (fr) Recepteur p95 de l'ovocyte du poussin (recepteur de lipomicrons/vitellogenine)

Legal Events

Date Code Title Description
FZDE Dead